Lonza reiterates outlook as big pharma may delay outsourcing decisions
Updated
Updated · The Wall Street Journal · May 8
Lonza reiterates outlook as big pharma may delay outsourcing decisions
10 articles · Updated · The Wall Street Journal · May 8
The Swiss contract drugmaker kept 2026 guidance for 11%-12% constant-currency sales growth and a core EBITDA margin above 32% after a strong first quarter.
It said large pharmaceutical companies' planned US investments could slow outsourcing decisions, but mainly reflect spending shifts to the US rather than a broader change in sourcing strategies.
Lonza said demand from big pharma and biotech remains sustained, with integrated biologics showing momentum, advanced synthesis helped by 2025 projects, and specialized modalities returning to healthy growth.
As U.S. policy pulls drug manufacturing onshore, will patients face higher costs for a more secure medicine supply?
Can the pharmaceutical industry truly achieve supply chain resilience, or is it just swapping one set of dependencies for another?